Mutual of America Capital Management LLC Cuts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Mutual of America Capital Management LLC lowered its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 3.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 261,885 shares of the biopharmaceutical company's stock after selling 9,712 shares during the period. Mutual of America Capital Management LLC's holdings in Bristol-Myers Squibb were worth $13,550,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in BMY. Capital International Investors boosted its stake in shares of Bristol-Myers Squibb by 14.1% in the 1st quarter. Capital International Investors now owns 70,203,814 shares of the biopharmaceutical company's stock worth $3,807,153,000 after buying an additional 8,675,322 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Bristol-Myers Squibb by 77.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,547,823 shares of the biopharmaceutical company's stock worth $680,469,000 after purchasing an additional 5,461,767 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Bristol-Myers Squibb by 86.3% during the 2nd quarter. Federated Hermes Inc. now owns 7,546,311 shares of the biopharmaceutical company's stock valued at $313,398,000 after purchasing an additional 3,495,704 shares during the last quarter. Swedbank AB bought a new stake in shares of Bristol-Myers Squibb during the 1st quarter worth $158,223,000. Finally, State of Michigan Retirement System boosted its holdings in shares of Bristol-Myers Squibb by 147.7% in the 2nd quarter. State of Michigan Retirement System now owns 4,767,133 shares of the biopharmaceutical company's stock worth $197,979,000 after buying an additional 2,842,400 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Wolfe Research began coverage on shares of Bristol-Myers Squibb in a research note on Friday. They issued a "peer perform" rating on the stock. Daiwa America raised Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Wednesday. Sanford C. Bernstein initiated coverage on Bristol-Myers Squibb in a research note on Thursday, October 17th. They issued a "market perform" rating and a $56.00 target price on the stock. TD Cowen increased their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a "hold" rating in a research note on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a "hold" rating on the stock in a research note on Tuesday, July 23rd. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, two have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $54.07.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat acquired 1,830 shares of Bristol-Myers Squibb stock in a transaction dated Friday, November 1st. The shares were purchased at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the transaction, the executive vice president now owns 62,109 shares of the company's stock, valued at $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of the business's stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares of the company's stock, valued at $654,091.20. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Stock Performance

NYSE:BMY traded down $2.28 during trading hours on Friday, hitting $56.22. The stock had a trading volume of 21,259,228 shares, compared to its average volume of 10,839,494. The company has a 50 day simple moving average of $52.73 and a two-hundred day simple moving average of $47.25. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.08.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.31. The company had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm's quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the company earned $2.00 earnings per share. On average, equities research analysts anticipate that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.27%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is -66.85%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.